Advertisement

Organisation › Details
Neurimmune AG
Neurimmune is a biopharmaceutical company dedicated to the development of human-derived therapeutic antibodies for the treatment and prevention of human diseases with a high unmet medical need. Established in 2006, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease, partnered with Biogen, is currently in phase 3 clinical trials. Rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were acquired by Biogen. In 2016, Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. In 2017, Neurimmune entered into a collaboration with Ono Pharmaceutical in Japan. Neurimmune’s pipeline includes human antibody programs for cardiomyopathy, type-2 diabetes and progressive multifocal leukoencephalopathy, with potential therapies in advanced preclinical stages. *
![]() |
Start | 2006-11-01 established |
![]() |
Industry | CNS drug (neurological drug) |
Industry 2 | RTM® technology (Reverse Translational Medicine) | |
![]() |
Person | Nitsch, Roger M. (Neurimmune 201809 CEO + Co-Founder + Evotec Biosystems 199906 Scientific Advisory Board) |
Person 2 | Salzmann, Michael (Neurimmune 2008– COO + General Manager before Bruker + Roche + ETH Zürich) | |
![]() |
Region | Schlieren ZH |
Country | Switzerland | |
Street | 13 Wagistr. Bio-Technopark | |
City | 8952 Schlieren ZH | |
Tel | +41-44-755-4646 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | A: 1 to 10 (2007-12-09) |
* Document for »About Section«: | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Neurimmune AG
- [1] Neurimmune AG. (1/17/22). "Press Release: Neurimmune Expands Drug Discovery Collaboration with Ono Pharmaceutical in the Field of Neurodegenerative Diseases". Zürich....
- [2] Neurimmune AG. (1/7/22). "Press Release: Neurimmune Enters into a Collaboration and License Agreement with AstraZeneca to Develop and Commercialize NI006". Zürich....
- [3] Neurimmune AG. (4/1/20). "Press Release: Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of Covid-19". Zurich & Munich....
- [4] Neurimmune AG. (3/1/19). "Press Release: Neurimmune Appoints John Dellapa as General Counsel". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top